BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...

Amneal Pharmaceuticals has submitted another new drug application (NDA) for its dihydroergotamine (DHE) prefilled syringe ...

The analyst notes that Amneal has moved its generics business from simple oral tablets to more complex products, which should support long-term growth. This shift, successful new product launches ...

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2024 results beating Wall Street’s revenue expectations , with sales up 18.4% year on year to $730.5 million.

In 2024, Amneal introduced a record number of new products, focusing on complex generics and biosimilars. The company’s ongoing investments in R&D and sales expansion aim to sustain long-term ...